Carboplatin, Paclitaxel and Gemcitabine Hydrochloride with or without Bevacizumab after Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IIITreatment18 and overGOG-0213
NCI-2009-00587, CDR0000546714, NCT00565851

Trial Description

Summary

This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer that has come back. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

II. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

SECONDARY OBJECTIVES:

I. To determine if the addition of bevacizumab to the second-line and maintenance phase of treatment increases the duration of progression-free survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

II. To prospectively determine the incidence of carboplatin and paclitaxel hypersensitivity in these patients undergoing retreatment with both agents as first recurrence therapy.

III. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases quality of life (QOL) in patients with recurrent platinum-sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer, as measured by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) trial outcome index and Rand Short Form (SF)-36 physical functioning scale.

IV. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases QOL relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum-sensitive epithelial ovarian, peritoneal primary or fallopian tube cancer.

TERTIARY OBJECTIVES:

I. To define molecular and biochemical profiles associated with the duration of progression-free survival in platinum-sensitive recurrent ovarian, peritoneal primary or fallopian tube carcinoma treated with combination chemotherapy with or without bevacizumab followed with or without maintenance bevacizumab therapy in the presence or absence of secondary surgical cytoreduction.

II. To identify molecular determinants that predict sensitivity or resistance to carboplatin and paclitaxel with or without bevacizumab followed with or without maintenance bevacizumab therapy.

III. To bank deoxyribonucleic acid (DNA) from whole blood for research and evaluate the association between single nucleotide polymorphisms (SNPs) and measures of clinical outcome including overall survival, progression-free survival and adverse events.

OUTLINE: Patients are assigned to 1 of 4 treatment groups. Patients who are not candidates for surgical cytoreduction (i.e., those for whom complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking) are eligible to receive chemotherapy after randomization.

Patients who are eligible for surgery undergo abdominal exploration with cytoreduction. Patients are then randomized to 1 of 4 treatment arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours or docetaxel IV over 1 hour and carboplatin IV over 60 minutes on day 1.

ARM II: Patients receive chemotherapy as in Arm I and bevacizumab IV over 30-90 minutes on day 1.

ARM III: Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.

ARM IV: Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.

In all arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients with measurable disease achieving a clinical response (CR) receive 6-8 courses of therapy. Patients with stable disease or partial regression receive a maximum of 8 courses.

Patients without measurable lesions as determined by a computed tomography (CT) scan prior to initiating study treatment continue therapy for 6 courses or, if cancer antigen (CA)-125 normalizes, for 2 courses beyond CA-125 normalization, whichever is greater. Patients in Arm II then receive a maintenance regimen comprising bevacizumab IV over 30-90 minutes. Treatment with bevacizumab alone repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically for 10 years.

Eligibility Criteria

Inclusion Criteria:

Patients must have met the pre-entry requirements as specified

A complete response to front-line chemotherapy must include: negative physical exam, negative pelvic exam and normalization of CA125, if elevated at baseline; although not required, any radiographic assessment of disease status (e.g. CT, magnetic resonance imaging [MRI], positron emission tomography [PET]/CT, etc) obtained following the completion of primary therapy should be considered negative for disease

This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients must have a urine protein-to-creatinine ratio (UPCR) < 1.0 mg/dL

Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

Patients must have signed an approved informed consent and authorization permitting release of personal health information

This eligibility criterion does not apply to patients enrolled after August 28, 2011; patients who are not candidates for surgical cytoreduction are eligible for the chemotherapy randomization; patients are not considered candidates for surgical cytoreduction if complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking

Alkaline phosphatase =< 2.5 times the upper limit of normal in the absence of liver metastasis; alkaline phosphatase < 5.0 times ULN in the presence of liver metastasis

Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal in the absence of liver metastasis; SGOT/AST < 5.0 times ULN in the presence of liver metastasis

Total bilirubin =< 1.5 ULN (CTCAE grade 1)

Creatinine (non-isotope dilution mass spectrometry [IDMS]) =< 1.5 x institutional upper limit normal (ULN), CTCAE grade 1

Platelets greater than or equal to 100,000/mm^3 (CTCAE grade 0-1)

Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to Common Toxicity Criteria for Adverse Events version (v)3.0 (CTCAE) grade 1

Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST]) is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be more than or equal to 20 mm when measured by conventional techniques, MRI or CT, or more than or equal to 10 mm when measured by spiral CT

Front-line treatment may include maintenance therapy following complete clinical or pathological response; however, maintenance cytotoxic chemotherapy must be discontinued for a minimum of 6 months prior to documentation of recurrent disease; patients receiving maintenance biological therapy or hormonal therapy are ELIGIBLE provided their recurrence is documented more than 6 months from primary cytotoxic chemotherapy completion (includes maintenance chemotherapy) AND a minimum 4 weeks has elapsed since their last infusion of biological therapy

All patients must have also had a treatment-free interval without clinical evidence of progressive disease of at least 6 months from completion of front-line chemotherapy (both platinum and taxane); front-line therapy may have included a biologic agent (i.e. bevacizumab)

Patients must have had a complete response to front-line platinum-taxane therapy (at least three cycles)

Patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's tumor, or adenocarcinoma not otherwise specified (N.O.S.)

Patients must have histologic diagnosis of epithelial ovarian carcinoma, peritoneal primary or fallopian tube carcinoma, which is now recurrent

Patients enrolled after August 28, 2011 must be candidates for cytoreductive surgery and consent to have their surgical treatment determined by randomization

Patients must have clinically evident recurrent disease for the purpose of this study

Exclusion Criteria:

Patients with a prior histologic diagnosis of borderline, low malignant potential (grade 0) epithelial carcinoma that was surgically resected and who subsequently developed an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible provided that they meet the criteria listed above

Patients whom have already undergone secondary cytoreduction for recurrent disease are excluded

This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients who have had a major surgical procedure, open biopsy, dental extractions or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this study

This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with a history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases or a history of stroke within 5 years of the first date of treatment on this study

This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with clinically significant cardiovascular disease; this includes:

Patients with significant cardiac conduction abnormalities, i.e. PR interval > 0.24 seconds (sec) or 2nd or 3rd degree atrioventricular (AV) block

Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg

Myocardial infarction, cardiac arrhythmia or unstable angina < 6 months prior to registration

New York Heart Association (NYHA) grade II or greater congestive heart failure

Serious cardiac arrhythmia requiring medication

Grade II or greater peripheral vascular disease (exception: episodes of ischemia < 24 hours [hrs] in duration, that are managed non-surgically and without permanent deficit)

History of cerebrovascular attack (CVA) within six months

This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major vessels

This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies

Patients undergoing pre-treatment surgery for purposes other than cytoreduction may also participate provided they meet eligibility; patients randomized to arms containing bevacizumab must wait a minimum of 28 days since that procedure to begin protocol treatment; patients who undergo an uncomplicated port placement must wait a minimum of 7 days to begin protocol treatment

Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy

Patients of childbearing potential, not practicing adequate contraception, patients who are pregnant or patients who are nursing are not eligible for this trial; bevacizumab should not be administered to nursing women

Patients with >= grade 2 peripheral neuropathy

Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy

Patients with uncontrolled infection

Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions

Patients who require parenteral hydration or nutrition and have evidence of partial bowel obstruction or perforation

Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded

Patients receiving concurrent immunotherapy, or radiotherapy

Patients who have received more than one previous regimen of chemotherapy (maintenance is not considered a second regimen)

Patients undergoing pre-treatment secondary cytoreduction will undergo therapy with bevacizumab on cycle #2

Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocol

Patients who have received prior chemotherapy for any abdominal or pelvic tumor (other than ovarian, fallopian tube, and primary peritoneal) are excluded

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

National Cancer Institute

  • National Cancer Institute
Robert L. Coleman, Principal Investigator

Trial Sites

U.S.A.

Alaska
Anchorage

Alaska Breast Care and Surgery LLC

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Alaska Women's Cancer Care

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Anchorage Oncology Centre

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Katmai Oncology Group

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Providence Alaska Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

California
Auburn

Sutter Auburn Faith Hospital

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Sutter Cancer Centers Radiation Oncology Services-Auburn

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Berkeley

Alta Bates Summit Medical Center-Herrick Campus

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Burlingame

Mills - Peninsula Hospitals

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Cameron Park

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Davis

Sutter Davis Hospital

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

La Jolla

UC San Diego Moores Cancer Center

Michael T. McHale
Ph: 858-822-5354
Email: cancercto@ucsd.edu

Michael T. McHale
Principal Investigator

Los Angeles

Kaiser Permanente Los Angeles Medical Center

Scott E. Lentz
Ph: 626-564-3455

Scott E. Lentz
Principal Investigator

UCLA / Jonsson Comprehensive Cancer Center

Robert L. Coleman
Ph: 713-792-3245
Email: rcoleman@mdanderson.org

Robert L. Coleman
Principal Investigator

Modesto

Memorial Medical Center

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Mountain View

Palo Alto Medical Foundation-Camino Division

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Palo Alto Medical Foundation-Gynecologic Oncology

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Palo Alto

Palo Alto Medical Foundation Health Care

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Stanford Cancer Institute

Jonathan S. Berek
Ph: 650-498-7061
Email: clinicaltrials@med.stanford.edu

Jonathan S. Berek
Principal Investigator

Roseville

Sutter Cancer Centers Radiation Oncology Services-Roseville

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Sutter Roseville Medical Center

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Sacramento

Sutter General Hospital

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

San Francisco

California Pacific Medical Center-Pacific Campus

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

UCSF Medical Center-Mount Zion

Lee-May Chen
Ph: 877-827-3222

Lee-May Chen
Principal Investigator

Santa Cruz

Palo Alto Medical Foundation-Santa Cruz

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Santa Rosa

Sutter Pacific Medical Foundation

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Sunnyvale

Palo Atlo Medical Foundation-Sunnyvale

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Vacaville

Sutter Cancer Centers Radiation Oncology Services-Vacaville

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Vallejo

Sutter Solano Medical Center/Cancer Center

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Colorado
Denver

Colorado Cancer Research Program CCOP

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Hartford

Saint Francis Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Middletown

Middlesex Hospital

Susanna Hong
Ph: 860-358-2058

Susanna Hong
Principal Investigator

Georgia
Augusta

Georgia Regents University Medical Center

Sharad Anant Ghamande
Ph: 706-721-1663
Email: cancer@georgiahealth.edu

Sharad Anant Ghamande
Principal Investigator

Columbus

John B Amos Cancer Center

Gregory Peter Sfakianos
Ph: 706-660-6404

Gregory Peter Sfakianos
Principal Investigator

Gainesville

Northeast Georgia Medical Center

Andrew Emmons Green
Ph: 770-219-8800
Email: cancerpatient.navigator@nghs.com

Andrew Emmons Green
Principal Investigator

Savannah

Low Country Cancer Care Associates PC

James Joseph Burke
Ph: 912-350-8568

James Joseph Burke
Principal Investigator

Memorial University Medical Center

James Joseph Burke
Ph: 912-350-8568

James Joseph Burke
Principal Investigator

Summit Cancer Care-Memorial

James Joseph Burke
Ph: 912-350-8568

James Joseph Burke
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Illinois
Bloomington

Illinois CancerCare-Bloomington

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Joseph Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Canton

Illinois CancerCare-Canton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carbondale

Memorial Hospital of Carbondale

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Centralia

Centralia Oncology Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Crossroads Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Eureka

Illinois CancerCare-Eureka

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Galesburg

Illinois CancerCare Galesburg

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Western Illinois Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Macomb

Illinois CancerCare-Macomb

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Mount Vernon

Good Samaritan Regional Health Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Radiation Oncology of Northern Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin

Illinois CancerCare-Pekin

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Illinois CancerCare-Peoria

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Methodist Medical Center of Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Illinois CancerCare-Peru

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Valley Radiation Oncology

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Princeton

Illinois CancerCare-Princeton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield

Central Illinois Hematology Oncology Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southern Illinois University School of Medicine

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Swansea

Cancer Care Specialists of Illinois-Swansea

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Indiana
Elkhart

Michiana Hematology Oncology PC-Elkhart

Michael Rodriguez
Ph: 574-237-1328

Michael Rodriguez
Principal Investigator

Mishawaka

Michiana Hematology Oncology PC-Mishawaka

Michael Rodriguez
Ph: 574-237-1328

Michael Rodriguez
Principal Investigator

Munster

The Community Hospital

Mohamad Kassar
Ph: 219-836-3349

Mohamad Kassar
Principal Investigator

Plymouth

Michiana Hematology Oncology PC-Plymouth

Michael Rodriguez
Ph: 574-237-1328

Michael Rodriguez
Principal Investigator

Richmond

Reid Hospital and Health Care Services

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

South Bend

Michiana Hematology Oncology PC-South Bend

Michael Rodriguez
Ph: 574-237-1328

Michael Rodriguez
Principal Investigator

Northern Indiana Cancer Research Consortium CCOP

Michael Rodriguez
Ph: 574-237-1328

Michael Rodriguez
Principal Investigator

Westville

Michiana Hematology Oncology PC-Westville

Michael Rodriguez
Ph: 574-237-1328

Michael Rodriguez
Principal Investigator

Iowa
Clive

Medical Oncology and Hematology Associates-West Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Cancer Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Council Bluffs

Alegent Health Mercy Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Des Moines

Iowa Lutheran Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Oncology Research Association CCOP

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Medical Oncology and Hematology Associates-Des Moines

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Medical Oncology and Hematology Associates-Laurel

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Medical Center - Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Iowa City

University of Iowa/Holden Comprehensive Cancer Center

David Paul Bender
Ph: 800-237-1225

David Paul Bender
Principal Investigator

West Des Moines

Mercy Medical Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Methodist West Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Kansas
Chanute

Cancer Center of Kansas - Chanute

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Dodge City

Cancer Center of Kansas - Dodge City

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

El Dorado

Cancer Center of Kansas - El Dorado

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Fort Scott

Cancer Center of Kansas - Fort Scott

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Independence

Cancer Center of Kansas-Independence

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kansas City

University of Kansas Cancer Center

Robert L. Coleman
Ph: 713-792-3245
Email: rcoleman@mdanderson.org

Robert L. Coleman
Principal Investigator

Kingman

Cancer Center of Kansas-Kingman

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Liberal

Cancer Center of Kansas-Liberal

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Newton

Cancer Center of Kansas - Newton

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Parsons

Cancer Center of Kansas - Parsons

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Pratt

Cancer Center of Kansas - Pratt

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Salina

Cancer Center of Kansas - Salina

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Wellington

Cancer Center of Kansas - Wellington

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Wichita

Associates In Womens Health

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Cancer Center of Kansas - Main Office

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Cancer Center of Kansas-Wichita Medical Arts Tower

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Via Christi Regional Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Winfield

Cancer Center of Kansas - Winfield

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Bardstown

Flaget Memorial Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Corbin

Commonwealth Cancer Center-Corbin

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Crestview Hills

Oncology Hematology Care Inc-Crestview

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Lexington

Saint Joseph Hospital East

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Saint Joseph Radiation Oncology Resource Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Louisville

Jewish Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Jewish Hospital Medical Center Northeast

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Saints Mary and Elizabeth Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Shepherdsville

Jewish Hospital Medical Center South

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Louisiana
Baton Rouge

Baton Rouge General Medical Center

William Russell Robinson
Ph: 504-988-6121

William Russell Robinson
Principal Investigator

Hematology/Oncology Clinic LLP

William Russell Robinson
Ph: 504-988-6121

William Russell Robinson
Principal Investigator

Woman's Hospital

Giles Fort
Ph: 225-231-5296
Email: Ericka.Seidemann@womans.org

Giles Fort
Principal Investigator

Marrero

West Jefferson Medical Center

William Russell Robinson
Ph: 504-988-6121

William Russell Robinson
Principal Investigator

New Orleans

Tulane University Health Sciences Center

William Russell Robinson
Ph: 504-988-6121

William Russell Robinson
Principal Investigator

Maryland
Baltimore

Greater Baltimore Medical Center

Amanda Nickles Fader
Ph: 410-955-8804
Email: jhcccro@jhmi.edu

Amanda Nickles Fader
Principal Investigator

Sinai Hospital of Baltimore

Fouad M. Abbas
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Fouad M. Abbas
Principal Investigator

Bethesda

Walter Reed National Military Medical Center

William J. Lowery
Ph: 301-319-2100

William J. Lowery
Principal Investigator

Randallstown

Northwest Hospital Center

Fouad M. Abbas
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Fouad M. Abbas
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

University of Michigan Comprehensive Cancer Center

Robert L. Coleman
Ph: 713-792-3245
Email: rcoleman@mdanderson.org

Robert L. Coleman
Principal Investigator

Battle Creek

Bronson Battle Creek

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Wayne State University/Karmanos Cancer Institute

Robert Thomas Morris
Ph: 313-576-9363

Robert Thomas Morris
Principal Investigator

Escanaba

Green Bay Oncology - Escanaba

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Farmington Hills

Weisberg Cancer Treatment Center

Robert Thomas Morris
Ph: 313-576-9363

Robert Thomas Morris
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Hurley Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Grand Rapids

Mercy Health Saint Mary's

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Spectrum Health at Butterworth Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Iron Mountain

Green Bay Oncology - Iron Mountain

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Jackson

Allegiance Health

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Lansing

Sparrow Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Muskegon

Mercy Health Mercy Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Niles

Lakeland Community Hospital

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Port Huron

Saint Joseph Mercy Port Huron

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Reed City

Spectrum Health Reed City Hospital

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Saginaw

Saint Mary's of Michigan

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Saint Joseph

Marie Yeager Cancer Center

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

St. Joseph

Lakeland Hospital

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Traverse City

Munson Medical Center

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Maria Caroline Bell
Ph: 218-333-5000

Maria Caroline Bell
Principal Investigator

Mississippi
Jackson

Saint Dominic-Jackson Memorial Hospital

Donald Paul Seago
Ph: 601-200-3300

Donald Paul Seago
Principal Investigator

Missouri
Bolivar

Central Care Cancer Center-Carrie J Babb Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Bonne Terre

Parkland Health Center-Bonne Terre

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Branson

CoxHealth Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Columbia

University of Missouri - Ellis Fischel

Mark Ira Hunter
Ph: 573-882-7440

Mark Ira Hunter
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Joplin

Freeman Health System

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital-Joplin

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint John's Clinic-Rolla-Cancer and Hematology

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Louis

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Missouri Baptist Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Louis Cancer and Breast Institute-South City

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Sainte Genevieve

Sainte Genevieve County Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Sullivan

Missouri Baptist Sullivan Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Nebraska
Grand Island

CHI Health Saint Francis

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Kearney

CHI Health Good Samaritan

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Heartland Hematology and Oncology

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Lincoln

Saint Elizabeth Regional Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Omaha

Alegent Health Bergan Mercy Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Alegent Health Immanuel Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Alegent Health Lakeside Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Creighton University Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Hemotology and Oncology Consultants PC

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Papillion

Midlands Community Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Nevada
Las Vegas

Women's Cancer Center of Nevada

Nicola M. Spirtos
Ph: 702-851-4672

Nicola M. Spirtos
Principal Investigator

Reno

Center of Hope at Renown Medical Center

Peter Christopher-Why Lim
Ph: 866-513-8227

Peter Christopher-Why Lim
Principal Investigator

Renown Regional Medical Center

Peter Christopher-Why Lim
Ph: 866-513-8227

Peter Christopher-Why Lim
Principal Investigator

New Jersey
Morristown

Morristown Medical Center

Daniel Henry Tobias
Ph: 973-971-5900

Daniel Henry Tobias
Principal Investigator

Neptune

Jersey Shore Medical Center

Karim Samir ElSahwi
Ph: 732-776-4240

Karim Samir ElSahwi
Principal Investigator

New Brunswick

Rutgers Cancer Institute of New Jersey

Darlene Grace Gibbon
Ph: 732-235-8675

Darlene Grace Gibbon
Principal Investigator

Phillipsburg

The Women's Institute for Gynecologic Cancer and Special Pelvic Surgery

David Foster Silver
Ph: 718-765-2500

David Foster Silver
Principal Investigator

Summit

Overlook Hospital

Daniel Henry Tobias
Ph: 973-971-5900

Daniel Henry Tobias
Principal Investigator

New Mexico
Albuquerque

Southwest Gynecologic Oncology Associates Inc

Carolyn Y. Muller
Ph: 505-272-6972

Carolyn Y. Muller
Principal Investigator

University of New Mexico

Robert L. Coleman
Ph: 713-792-3245
Email: rcoleman@mdanderson.org

Robert L. Coleman
Principal Investigator

University of New Mexico Cancer Center

Carolyn Y. Muller
Ph: 505-272-6972

Carolyn Y. Muller
Principal Investigator

Las Cruces

Memorial Medical Center - Las Cruces

Carolyn Y. Muller
Ph: 505-272-6972

Carolyn Y. Muller
Principal Investigator

New York
Albany

Women's Cancer Care Associates LLC

Daniel Casey Kredentser
Ph: 518-458-1390

Daniel Casey Kredentser
Principal Investigator

Manhasset

North Shore University Hospital

Veena Susan John
Ph: 516-562-3467

Veena Susan John
Principal Investigator

New Hyde Park

Long Island Jewish Medical Center

Veena Susan John
Ph: 516-562-3467

Veena Susan John
Principal Investigator

North Shore-LIJ Health System/Center for Advanced Medicine

Veena Susan John
Ph: 516-562-3467

Veena Susan John
Principal Investigator

New York

Mount Sinai Medical Center

Jamal Rahaman
Ph: 212-824-7320
Email: jenny.figueroa@mssm.edu

Jamal Rahaman
Principal Investigator

Syracuse

State University of New York Upstate Medical University

Mary Jadhon Cunningham
Ph: 315-464-5476

Mary Jadhon Cunningham
Principal Investigator

North Carolina
Asheboro

Randolph Hospital

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Burlington

Cone Health Cancer Center at Alamance Regional

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Durham

Duke University Medical Center

Angeles Alvarez Secord
Ph: 888-275-3853

Angeles Alvarez Secord
Principal Investigator

Greensboro

Cone Health Cancer Center

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Mebane

Cone Heath Cancer Center at Mebane

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Pinehurst

FirstHealth of the Carolinas-Moore Regional Hosiptal

Michael John Sundborg
Ph: 910-715-2200

Michael John Sundborg
Principal Investigator

Raleigh

Duke Raleigh Hospital

Angeles Alvarez Secord
Ph: 888-275-3853

Angeles Alvarez Secord
Principal Investigator

Reidsville

Annie Penn Memorial Hospital

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Winston-Salem

Wake Forest University Health Sciences

Samuel Smith Lentz
Ph: 336-713-6771

Samuel Smith Lentz
Principal Investigator

North Dakota
Fargo

Roger Maris Cancer Center

Maria Caroline Bell
Ph: 218-333-5000

Maria Caroline Bell
Principal Investigator

Sanford Clinic North-Fargo

Maria Caroline Bell
Ph: 218-333-5000

Maria Caroline Bell
Principal Investigator

Sanford Medical Center-Fargo

Maria Caroline Bell
Ph: 218-333-5000

Maria Caroline Bell
Principal Investigator

Ohio
Belpre

Strecker Cancer Center-Belpre

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Canton

Aultman Health Foundation

Michael P. Hopkins
Ph: 330-363-6891

Michael P. Hopkins
Principal Investigator

Centerville

Miami Valley Hospital South

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Chillicothe

Adena Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Cincinnati

Bethesda North Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Good Samaritan Hospital - Cincinnati

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Oncology Hematology Care Inc - Anderson

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc - Kenwood

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Blue Ash

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Eden Park

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Mercy West

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

TriHealth Cancer Institute-Anderson

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

TriHealth Cancer Institute-Westside

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Cleveland

Case Western Reserve University

Steven E. Waggoner
Ph: 800-641-2422

Steven E. Waggoner
Principal Investigator

Cleveland Clinic Cancer Center/Fairview Hospital

Peter G. Rose
Ph: 866-223-8100

Peter G. Rose
Principal Investigator

Cleveland Clinic Foundation

Peter G. Rose
Ph: 866-223-8100

Peter G. Rose
Principal Investigator

Columbus

Columbus Oncology and Hematology Associates Inc

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Doctors Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Grant Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Mount Carmel Health Center West

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Ohio State University Comprehensive Cancer Center

Robert L. Coleman
Ph: 713-792-3245
Email: rcoleman@mdanderson.org

Robert L. Coleman
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Dayton

Good Samaritan Hospital - Dayton

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Samaritan North Health Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Delaware

Delaware Health Center-Grady Cancer Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Delaware Radiation Oncology

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Grady Memorial Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Fairfield

Oncology Hematology Care Inc-Healthplex

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Findlay

Blanchard Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Franklin

Atrium Medical Center-Middletown Regional Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Greenville

Wayne Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Kettering

Kettering Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Lancaster

Fairfield Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Marietta

Marietta Memorial Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Mayfield Heights

Hillcrest Hospital Cancer Center

Peter G. Rose
Ph: 866-223-8100

Peter G. Rose
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Steven E. Waggoner
Ph: 800-641-2422

Steven E. Waggoner
Principal Investigator

Mount Vernon

Knox Community Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Newark

Licking Memorial Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Newark Radiation Oncology

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Springfield

Springfield Regional Cancer Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Springfield Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Troy

Upper Valley Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Westerville

Saint Ann's Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Zanesville

Genesis HealthCare System

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Robert S. Mannel
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Robert S. Mannel
Principal Investigator

Tulsa

Tulsa Cancer Institute

Robert S. Mannel
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Robert S. Mannel
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Providence Oncology and Hematology Care Southeast

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Newberg

Providence Newberg Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Oregon City

Providence Willamette Falls Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Portland

Providence Portland Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Providence Saint Vincent Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Parviz Hanjani
Ph: 215-481-2402

Parviz Hanjani
Principal Investigator

Allentown

Lehigh Valley Hospital-Cedar Crest

Alyson F. McIntosh
Ph: 610-402-2273

Alyson F. McIntosh
Principal Investigator

Bethlehem

Lehigh Valley Hospital - Muhlenberg

Alyson F. McIntosh
Ph: 610-402-2273

Alyson F. McIntosh
Principal Investigator

Danville

Geisinger Medical Center

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Hazleton

Geisinger Medical Center-Cancer Center Hazleton

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Hershey

Penn State Milton S Hershey Medical Center

James Fanning
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

James Fanning
Principal Investigator

Philadelphia

Fox Chase Cancer Center

Stephen C. Rubin
Ph: 215-728-4790

Stephen C. Rubin
Principal Investigator

University of Pennsylvania/Abramson Cancer Center

Robert Allen Burger
Ph: 215-746-7406

Robert Allen Burger
Principal Investigator

Pittsburgh

West Penn Hospital

Thomas Carl Krivak
Ph: 412-578-5000

Thomas Carl Krivak
Principal Investigator

State College

Geisinger Medical Group

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

West Reading

Reading Hospital

Bernice L. Robinson-Bennett
Ph: 610-988-9323

Bernice L. Robinson-Bennett
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Rhode Island
Providence

Women and Infants Hospital

Paul A. DiSilvestro
Ph: 401-274-1122

Paul A. DiSilvestro
Principal Investigator

South Dakota
Sioux Falls

Sanford Cancer Center-Oncology Clinic

Maria Caroline Bell
Ph: 218-333-5000

Maria Caroline Bell
Principal Investigator

Sanford USD Medical Center - Sioux Falls

Maria Caroline Bell
Ph: 218-333-5000

Maria Caroline Bell
Principal Investigator

Tennessee
Bristol

Wellmont Bristol Regional Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Wellmont Medical Associates Oncology and Hematology-Bristol

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Chattanooga

Memorial Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Hixson

Pulmonary Medicine Center of Chattanooga-Hixson

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Kingsport

Wellmont Holston Valley Hospital and Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Wellmont Medical Associates Oncology and Hematology-Kingsport

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Ooltewah

Memorial GYN Plus

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Texas
Austin

University Medical Center Brackenridge

Mark Allen Crozier
Ph: 512-324-7991

Mark Allen Crozier
Principal Investigator

Dallas

Parkland Memorial Hospital

David Scott Miller
Ph: 214-648-7097

David Scott Miller
Principal Investigator

UT Southwestern/Simmons Cancer Center-Dallas

David Scott Miller
Ph: 214-648-7097

David Scott Miller
Principal Investigator

Utah
American Fork

American Fork Hospital / Huntsman Intermountain Cancer Center

Ross Eric Morgan
Ph: 801-581-4477
Email: clinical.trials@hci.utah.edu

Ross Eric Morgan
Principal Investigator

Salt Lake City

Huntsman Cancer Institute/University of Utah

Theresa Louise Werner
Ph: 801-581-4477
Email: clinical.trials@hci.utah.edu

Theresa Louise Werner
Principal Investigator

Vermont
Burlington

University of Vermont Medical Center

Cheung Wong
Ph: 802-656-8990

Cheung Wong
Principal Investigator

Virginia
Charlottesville

University of Virginia Cancer Center

Susan Carnall Modesitt
Ph: 434-243-6143

Susan Carnall Modesitt
Principal Investigator

Norton

Southwest VA Regional Cancer Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Richmond

Virginia Commonwealth University/Massey Cancer Center

Weldon E. Chafe
Ph: 804-628-1939

Weldon E. Chafe
Principal Investigator

Roanoke

Carilion Clinic Gynecological Oncology

Janet L. Osborne
Ph: 540-985-8510

Janet L. Osborne
Principal Investigator

Washington
Bremerton

Harrison HealthPartners Hematology and Oncology-Bremerton

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Harrison Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Burien

Highline Medical Center-Main Campus

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Enumclaw

Saint Elizabeth Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Federal Way

Saint Francis Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Lakewood

Saint Clare Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Longview

Saint John Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Poulsbo

Harrison HealthPartners Hematology and Oncology-Poulsbo

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Seattle

Virginia Mason CCOP

Amy D. Brockmeyer
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Amy D. Brockmeyer
Principal Investigator

Virginia Mason Medical Center

Amy D. Brockmeyer
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Amy D. Brockmeyer
Principal Investigator

Tacoma

Franciscan Research Center-Northwest Medical Plaza

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Northwest Medical Specialties PLLC

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Vancouver

PeaceHealth Southwest Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Wisconsin
Fond Du Lac

Aurora Health Center-Fond du Lac

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Green Bay

Aurora BayCare Medical Center

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Green Bay Oncology at Saint Vincent Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Green Bay Oncology Limited at Saint Mary's Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Saint Mary's Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Saint Vincent Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Marinette

Bay Area Medical Center

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Vince Lombardi Cancer Clinic-Marinette

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Milwaukee

Aurora Saint Luke's Medical Center

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Froedtert and the Medical College of Wisconsin

William H. Bradley
Ph: 414-805-4380

William H. Bradley
Principal Investigator

Medical Consultants Limited

Robert L. Coleman
Ph: 713-792-3245
Email: rcoleman@mdanderson.org

Robert L. Coleman
Principal Investigator

Oconto Falls

Green Bay Oncology - Oconto Falls

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Sheboygan

Vince Lombardi Cancer Clinic-Sheboygan

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Sturgeon Bay

Green Bay Oncology - Sturgeon Bay

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Summit

Aurora Medical Center in Summit

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Two Rivers

Vince Lombardi Cancer Clinic

Ali Mahdavi
Ph: 414-649-5717

Ali Mahdavi
Principal Investigator

Japan

Kure

Kure National Hospital

Kazuhiro Takehara
Ph: 089-999-1172

Kazuhiro Takehara
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00565851

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.